CGNI — Cardiogeni Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.01 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.8 | ||
| EV to EBITDA | 1.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 361.57% | ||
| Return on Equity | n/a | ||
| Operating Margin | 38.73% | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 244.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cardiogeni Plc, formerly Celixir Limited, is a United Kingdom-based clinical development stage bio-pharmaceutical company. The principal activity of the Company is the development and commercialization of a portfolio of novel cellular medicines for heart failure. The Company's platform technology enables the creation of unique (living) cells that are engineered with a therapeutic function. The Company's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which are administered during coronary artery bypass grafting surgery. CLXR-001 targets heart failure and consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration.
Directors
- Darrin Disley CHM (57)
- Ajan Reginald EDR (53)
- Martin Evans CSO (84)
- Joanne Martin NID (65)
- Chaim Hurvitz NID (66)
- James Bethell NID (57)
- Last Annual
- Last Interim
- Incorporated
- December 28th, 2016
- Public Since
- January 31st, 2025
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Aquis Stock Exchange
- Shares in Issue
- 89,103,756
- Address
- STRATFORD-UPON-AVON, CV37 7GZ
- Web
- https://cardiogeni.com/
- Phone
- Auditors
- Grenfell James LLP
Similar to CGNI
Tomahawk Metals
Aquis Stock Exchange
FAQ
As of Today at 24:49 UTC, shares in Cardiogeni are trading at 7.00p. This share price information is delayed by 15 minutes.
Shares in Cardiogeni last closed at 7.00p and the price had moved by -22.22% over the past 365 days. In terms of relative price strength the Cardiogeni share price has underperformed the FTSE All Share Index by -29.91% over the past year.
There is no consensus recommendation for this security.
Find out moreCardiogeni does not currently pay a dividend.
Cardiogeni does not currently pay a dividend.
Cardiogeni does not currently pay a dividend.
To buy shares in Cardiogeni you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 7.00p, shares in Cardiogeni had a market capitalisation of .
Here are the trading details for Cardiogeni:
- Country of listing: United Kingdom
- Exchange: AQS
- Ticker Symbol: CGNI
Based on an overall assessment of its quality, value and momentum Cardiogeni is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cardiogeni. Over the past six months, its share price has underperformed the FTSE All Share Index by -5.07%.
As of the last closing price of 7.00p, shares in Cardiogeni were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cardiogeni PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 7.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cardiogeni's management team is headed by:
- Darrin Disley - CHM
- Ajan Reginald - EDR
- Martin Evans - CSO
- Joanne Martin - NID
- Chaim Hurvitz - NID
- James Bethell - NID